Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
Cheap money, artificial credit, and zero interest policies have created all sorts of bubbles since the financial crisis of 2008. Dominic Frisby looks at three that are ready to pop.
David Thornton looks at one small Aim-listed biotech company that has the product and the management behind it to succeed.
This tiny university spin-out company has developed two ingenious new uses for ultrasound. David Thornton looks at its prospects.
The Nasdaq Biotechnology index has risen almost sixfold in the past ten year. In the past five, it has quadrupled.
Biotechnology firms are benefiting from demand from ageing populations. But as Dr Daniel Koller explains, there’s more to the biotech boom than that.
AstraZeneca’s interest in a small biotech firm is a reminder of why tiny drug companies are so important, says David Thornton.
Neil Woodford’s new start-up fund will get plenty of hype, says David Thornton. But penny share investors should buy this stock instead.
Investment manager Carl Harald Janson tips three biotech stocks to profit from the full range of opportunities this exciting sector has to offer.
The field of gene therapy struggled at first – to the point where some doubted it altogether. But 2014 saw some outstanding successes, says Tom Bulford.
Science is only just getting to grips with the fact that 90% of our body is made up of bacteria – the microbiome. Bengt Saelensminde investigates.